How big is Eton Pharmaceuticals, Inc.?

As of Jun 18, Eton Pharmaceuticals, Inc. has a market capitalization of 364.99 million and reported net sales of 48.32 million with a net profit of -4.58 million over the last four quarters. Shareholder's funds are 24.43 million, and total assets are 76.12 million as of Dec 24.

As of Jun 18, Eton Pharmaceuticals, Inc. has a market capitalization of 364.99 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 48.32 million, while the sum of net profit for the same period is -4.58 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 24.43 million, and total assets are reported at 76.12 million.

What does Eton Pharmaceuticals, Inc. do?

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products. As of March 2025, it reported net sales of $17 million and a net loss of $2 million, with a market cap of approximately $365 million.

Overview:<BR>Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products in the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 17 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 364.99 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.52 <BR>Return on Equity: -16.07% <BR>Price to Book: 14.93<BR><BR>Contact Details:<BR>Address: 21925 W Field Pkwy Ste 235, DEER PARK IL: 60010-7208 <BR>Tel: 1 847 7877361 <BR>Website: https://etonpharma.com/

Should I buy, sell or hold Eton Pharmaceuticals, Inc.?

Who are in the management team of Eton Pharmaceuticals, Inc.?

As of March 2022, the management team of Eton Pharmaceuticals, Inc. includes Dr. Norbert Riedel (Independent Chairman), Mr. Sean Brynjelsen (President and CEO), Mr. Mark Baum (Director), and independent directors Mr. Charles Casamento and Mr. Paul Maier. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Eton Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Norbert Riedel, who serves as the Independent Chairman of the Board.<BR>- Mr. Sean Brynjelsen, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Mark Baum, who holds the position of Director.<BR>- Mr. Charles Casamento, who is an Independent Director.<BR>- Mr. Paul Maier, who is also an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Eton Pharmaceuticals, Inc. overvalued or undervalued?

As of August 8, 2024, Eton Pharmaceuticals, Inc. is considered risky and overvalued due to poor financial metrics, including a negative P/E ratio and high Price to Book Value, despite a strong stock performance.

As of 8 August 2024, the valuation grade for Eton Pharmaceuticals, Inc. has moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued, particularly given its negative P/E ratio and poor return metrics. Key ratios include a Price to Book Value of 18.47, an EV to EBITDA of 464.26, and a ROE of -16.07%. <BR><BR>In comparison to its peers, Eton's valuation metrics are significantly worse; for instance, Esperion Therapeutics, Inc. has a P/E of -4.99 and an EV to EBITDA of -28.92, while Protalix Biotherapeutics, Inc. shows a more attractive P/E of 20.08 and an EV to EBITDA of 9.80. Despite Eton's impressive stock performance, with a 1Y return of 212.35% compared to the S&P 500's 17.14%, the underlying financial metrics suggest that the stock is not supported by its fundamentals.

Is Eton Pharmaceuticals, Inc. technically bullish or bearish?

As of August 26, 2025, Eton Pharmaceuticals, Inc. has shifted to a bullish trend, supported by positive signals from MACD, Bollinger Bands, and moving averages, while outperforming the S&P 500 with a 1-year return of 212.35%.

As of 26 August 2025, the technical trend for Eton Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish, supported by bullish signals in both the weekly and monthly MACD, Bollinger Bands, and KST. Daily moving averages also indicate a bullish trend. While the RSI shows no signal, Dow Theory and OBV are mildly bullish on both weekly and monthly time frames. Eton has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 212.35% compared to the S&P 500's 17.14%.